Compounds > temozolomide
Page last updated: 2024-11-04

temozolomide and Neoplasms

temozolomide has been researched along with Neoplasms in 138 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM) in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting."9.11A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ( Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR, 2004)
"Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor."8.02AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021)
"Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined."5.62Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. ( Becker, C; Bergsland, EK; Chan, DL; Chan, JA; Gadgil, R; Halfdanarson, TR; Hornbacker, K; Kelly, V; Kunz, PL; McGarrah, PW; Raj, NP; Reidy, DL; Singh, S; Thawer, A; Whitman, J; Wu, L, 2021)
"Temozolomide (TMZ) is an oral alkylating agent used in the treatment of central nervous system neoplasms and metastatic melanoma."5.17A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. ( Beelen, AP; Coker, SA; Crosby, NA; Dandamudi, UB; Ernstoff, MS; Fisher, JL; Lewis, LD; Obrocea, M, 2013)
" The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM) in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting."5.11A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. ( Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR, 2004)
"Temozolomide, a methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanoma, and mycosis fungoides and is presently administered as a 5-day oral schedule every 4 weeks."5.08Phase I trial of temozolomide using an extended continuous oral schedule. ( Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR, 1998)
" The most striking evidence for proautophagic chemotherapy to overcome apoptosis resistance in cancer cells comes from the use of temozolomide, a proautophagic cytotoxic drug, which has demonstrated real therapeutic benefits in glioblastoma patients and is in clinical trials for several types of apoptosis-resistant cancers."4.84Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. ( Facchini, V; Kiss, R; Lefranc, F, 2007)
"The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs)."4.12Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience. ( Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM, 2022)
"Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor."4.02AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021)
" Second, we demonstrate that a combination of temozolomide and an experimental therapy in a glioma PDX model yields an effect, similar to an additive version of the DTE curves for the mono-therapies, except that there is a 30 day delay in peak inhibition."3.81Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. ( Ashcraft, KA; Boss, MK; Choudhury, KR; Dewhirst, MW; Keir, ST, 2015)
"Metformin shows preclinical anti-cancer activity through multiple pathways."3.30A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023)
" This phase I study evaluated the pharmacokinetics and mass balance of veliparib administered alone and in combination with temozolomide, and assessed any potential pharmacokinetic drug-drug interaction between veliparib and temozolomide."2.87Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. ( Giranda, V; Munasinghe, W; Nuthalapati, S; Xiong, H, 2018)
"Pyrimethamine is an antiparasitic drug used for the treatment of malaria and toxoplasmosis with a well-documented excellent safety profile."2.82The multifaceted antineoplastic role of pyrimethamine against human malignancies. ( Ahn, KS; Mistry, JR; Mohan, CD; Naz, I; Ramchandani, S; Rangappa, KS; Su, Q, 2022)
"Cancer is one of the main causes of human mortality and brain tumors, including invasive pituitary adenomas, medulloblastomas and glioblastomas are common brain malignancies with poor prognosis."2.82Oxamate targeting aggressive cancers with special emphasis to brain tumors. ( Altinoz, MA; Ozpinar, A, 2022)
" Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 h*μg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 h*μg/mL for gemcitabine and erlotinib)."2.80An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. ( Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD, 2015)
"Twenty-six patients received CEP-9722 150-1,000 mg/day combined with temozolomide."2.79Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. ( Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P, 2014)
"The median number of brain metastases was 1."2.77Chemosensitized radiosurgery for recurrent brain metastases. ( Fortin, MA; Pouliot, JF; Roberge, D; Souhami, L, 2012)
"Bortezomib was administered on days 2, 5, 9, and 12; temozolomide on days 1-5 of a 28-day cycle."2.77A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ( Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012)
"Irinotecan was given IV over 1 hr on days 1-5 and 8-12."2.75Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. ( Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN, 2010)
"To evaluate maximum tolerated dose and recommended dose (RD) for phase II studies of topotecan (TPT) combined with temozolomide (TMZ) (TOTEM) in children and adolescents with relapsed or refractory solid malignancies."2.75Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. ( Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G, 2010)
"Temozolomide was given on days 1-5, with vincristine 1."2.75Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. ( Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM, 2010)
"Temozolomide was administered orally, daily for 5 days starting at 28 mg/m(2) per day with escalations to 40, 55, 75 and 100 mg/m(2) per day with O(6)BG intravenously daily for 5 days at doses of 60, 90 or 120 mg/m(2) per day."2.74Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. ( Aikin, AA; Balis, FM; Cole, DE; Fox, E; Meany, HJ; Warren, KE, 2009)
"Thalidomide 100 mg was kept stable for all cohorts."2.73A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007)
"Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon."2.73Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. ( Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I, 2008)
" The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy."2.73Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. ( Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R, 2008)
"Lomeguatrib was administered at dose levels of 10 to 40 mg/m2 days 1 to 5, as a single agent, and also in combination with temozolomide."2.72Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. ( Bridgewater, J; Dawson, M; Donnelly, D; Gumbrell, L; Halbert, G; Jowle, D; Lee, SM; Margison, GP; McElhinney, RS; McGrath, H; McMurry, TB; Middleton, MR; Ranson, M; Waller, S, 2006)
"Malignant tumors in young patients present a significant therapeutic challenge for physicians, partially due to their rarity and a relative lack of data, at least compared to adult tumors."2.72An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors. ( Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S, 2021)
" Cisplatin-temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m(-2) cisplatin and 150 mg m(-2) x 5 temozolomide in heavily treated, and 200 mg m(-2) x 5 temozolomide in less-heavily pretreated children."2.71Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. ( Chastagner, P; Couanet, D; Djafari, L; Doz, F; Frappaz, D; Gentet, JC; Geoerger, B; Geoffray, A; Margison, GP; O'Quigley, J; Pein, F; Raquin, MA; Rubie, H; Vassal, G; Wartelle, M; Watson, AJ, 2005)
"Temozolomide (Temodal) is an oral imidazotetrazine."2.71Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. ( Awada, A; de Valeriola, D; Dubuisson, M; Gil, T; Klastersky, J; Moerman, C; Piccart, MJ; Sales, F; Vereecken, P, 2004)
"Temozolomide 500 mg/m2 was administered as a single oral dose every 28 days."2.71Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. ( Baker, SD; Batra, VK; Cutler, DL; Donehower, RC; Rudek, MA; Statkevich, P, 2004)
" Patients have received irinotecan and temozolomide on one of three different dosing schedules: (1) oral temozolomide on days 1-14 plus a single i."2.71Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. ( Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT, 2003)
"Temozolomide (TMZ) is a methylating agent of the imidotetrazine class, whose cytotoxic product is O(6)-methylguanine DNA adducts, which initiate a futile recycling of the mismatch repair pathway causing DNA strand breaks and apoptotic cell death in mismatch repair proficient cells."2.70Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. ( Gerson, SL; Haaga, J; Liu, L; Majka, S; Spiro, TP; Willson, JK, 2001)
"Temozolomide was administered orally daily for 5 days, with subsequent courses administered every 21 to 28 days after full hematologic recovery."2.69Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. ( Ames, MM; Ettinger, AG; Krailo, M; Liu-Mares, W; Nicholson, HS; Reaman, GH; Reid, JM; Seibel, NL; Vezina, LG, 1998)
"Temozolomide is an imidazotetrazine alkylating agent which undergoes chemical conversion at physiological pH to the active species 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide (MTIC) but is stable at acid pH."2.69Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. ( Beale, P; Brada, M; Cutler, DL; Judson, I; Marco, A; Moore, S; Reidenberg, P; Statkevich, P, 1999)
"90 hours, on average, and elimination was rapid, with a half-life and systemic clearance rate (Cl(S/F)) averaging 1."2.69Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. ( Baker, SD; Dugan, M; Eckardt, JR; Eckhardt, SG; Forral, K; Hammond, LA; Reidenberg, P; Rinaldi, DA; Rowinsky, EK; Statkevich, P; Von Hoff, DD; Weiss, GR, 1999)
" Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1."2.69Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ( Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999)
"Temozolomide (TMZ) is an oral imidazotetrazinone that is spontaneously converted to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH."2.69A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ( Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD, 1999)
"Temozolomide (TMZ) is a new imidazotetrazine derivative with early clinical activity in glioma and melanoma."2.68Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. ( Ames, MM; Buckner, JC; Burch, PA; Dhodapkar, M; Pitot, HC; Reid, JM; Rubin, J; Suman, VJ, 1997)
"Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2."2.67Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992)
"Anticancer agents are critical for the cancer treatment, but side effects and the drug resistance associated with the currently used anticancer agents create an urgent need to explore novel drugs with low side effects and high efficacy."2.611,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. ( Liu, Y; Xu, Z; Zhao, SJ, 2019)
"Temozolomide (TMZ) is an alkylating agent that is widely used in chemotherapy for cancer."2.50Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. ( Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Xin, Y; Zheng, JN, 2014)
"Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma."2.49Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013)
"Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit."2.49Temozolomide-related hematologic toxicity. ( De Sanctis, V; Enrici, RM; Minniti, G; Scaringi, C, 2013)
"Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide."2.46The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. ( Bei, R; Marzocchella, L; Turriziani, M, 2010)
"Temozolomide (TMZ) has demonstrated clinical antitumor activity."2.45The safety of temozolomide in the treatment of malignancies. ( Hwu, WJ; Patel, SP; Trinh, VA, 2009)
" Attempts to maximise efficacy have led to manipulation of both dosage and drug scheduling and the evidence for the various strategies is reviewed."2.43Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. ( Middleton, MR; Payne, MJ; Pratap, SE, 2005)
" Extended dosing has met with early favourable results."2.43Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. ( Middleton, MR; Sabharwal, A, 2006)
"The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens."2.41Novel oral chemotherapy agents. ( Hoff, PM; Pazdur, R; Royce, ME, 2000)
"Fifty per cent of all cancers occur in this age group and therefore there will be an expected rise in the total cancer burden."2.41Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. ( Lichtman, SM; Skirvin, JA, 2002)
"Clinical efficacy of DNA-damaging anticancer drugs can be influenced by the DNA damage response in tumor cells."1.91Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. ( Coussens, NP; Dexheimer, TS; Doroshow, JH; Morris, J; Silvers, T; Teicher, BA; Wright, J, 2023)
"Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined."1.62Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. ( Becker, C; Bergsland, EK; Chan, DL; Chan, JA; Gadgil, R; Halfdanarson, TR; Hornbacker, K; Kelly, V; Kunz, PL; McGarrah, PW; Raj, NP; Reidy, DL; Singh, S; Thawer, A; Whitman, J; Wu, L, 2021)
"For certain cancer types, such as melanoma, gene body methylation appears to be a better predictor of MGMT transcription (compared to promoter methylation)."1.62MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types. ( Bacolod, MD; Barany, F, 2021)
"DynaFit revealed that cell fitness in cancer cell lines, primary cancer cells, and fibroblasts under unhindered growth conditions is dynamic."1.62Cancer Cell Fitness Is Dynamic. ( Begnini, KR; Bracco, PA; Buss, JH; Callegari-Jacques, SM; Dalsin, E; Faccioni, JL; Lenz, G; Lenz, LS; Mantovani, GB; Marcolin, JC; Monteiro, T; Onzi, GR; Pereira, LC; Santo, CN; Santos, JAF; Silva, AO; Tamborindeguy, MT; Torgo, D; Vigo, A, 2021)
"A murine model of lung cancer was also used."1.56Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells. ( Bougras-Cartron, G; Briand, J; Campone, M; Cartron, PF; Frenel, JS; Garnier, D; Guyon, N; Heymann, D; Nadaradjane, A; Raimbourg, J; Vallette, FM, 2020)
"Methionine (MET) is a general target in cancer due to the excess requirement of MET by cancer cells."1.51High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. ( Han, Q; Hoffman, RM; Igarashi, K; Kawaguchi, K; Li, S; Murakami, T; Tan, Y, 2019)
"To test our hypothesis, three murine cancer cells were infected with OAd (E1b-deleted) alone or in combination with TMZ."1.48Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis. ( Garza-Morales, R; Gomez-Gutierrez, JG; McMasters, KM; Montes de Oca-Luna, R; Perez-Hernandez, R; Riedinger, E; Shirwan, H; Yaddanapudi, K; Yolcu, E, 2018)
" Its high bioavailability (40%~100%) and high tissue distribution in both monkeys and rats were its most important pharmacokinetic features."1.46Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. ( Chen, CH; Chen, XY; Chen, Y; Ding, J; Gao, ZW; He, JX; He, Q; Huan, XJ; Li, XH; Liao, XM; Lu, XL; Miao, ZH; Shen, YY; Song, SS; Su, Y; Sun, YM; Tan, C; Tong, LJ; Wang, M; Wang, YQ; Wang, YT; Xiong, B; Yang, CH; Yang, XY, 2017)
"In addition, tumors often develop multidrug resistance based on the cellular efflux of chemotherapeutic agents."1.42Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells. ( Aksenov, AV; Aksenov, NA; Aksenova, IV; Brenner, AJ; Bryan, BA; Cavazos, DA; Correa, J; De Carvalho, A; Frolova, LV; Johnston, RK; Kiss, R; Kornienko, A; Lefranc, F; Magedov, IV; Mathieu, V; Nguyen, G; Pendleton, AL; Reisenauer, MR; Rogelj, S; Rubin, M; Smirnov, AN, 2015)
"Most patients with brain metastases have active extracranial disease, which limits survival unless effective systemic therapy can be administered."1.40Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases. ( Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A, 2014)
"Temozolomide (TMZ) is an antineoplastic alkylating agent with activity against serious and aggressive types of brain tumours."1.39In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction. ( Lopes, IC; Oliveira, SC; Oliveira-Brett, AM, 2013)
"Temozolomide was tested against the PPTP solid tumor and ALL models."1.39Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. ( Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Wu, J, 2013)
"The major dilemma of cancer chemotherapy has always been a double-edged sword, producing resistance in tumor cells and life-threatening destruction of nontumorigenic tissue."1.39Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. ( Gupte, M; Sharma, VP; Tuck, AN; Williams, KJ, 2013)
"A retrospective study assessing treatment-related toxicities in tumor-bearing cats treated with temozolomide (TMZ) alone or in combination with doxorubicin was conducted."1.38Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment. ( Dervisis, NG; Gagnon, J; Kitchell, BE, 2012)
"Temozolomide response was analyzed in vitro and in vivo."1.35Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? ( Ali, M; Curtin, NJ; Hirst, DG; Kamjoo, M; Kyle, S; McCrudden, C; O'Rourke, M; Robson, T; Shaw, C; Telfer, BA; Thomas, HD; Williams, KJ, 2009)
"Treatment with temozolomide combined with AMG 102 resulted in increased inhibition of cell growth in vitro compared with treatment with either single agent alone."1.34AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. ( Burgess, TL; Coxon, A; Jun, HT; Kendall, R; Radinsky, R; Rex, K; Sun, J, 2007)
"The response of solid tumors to antitumor treatment generally declines markedly with treatment time."1.32Modeling antitumor activity by using a non-linear mixed-effects model. ( Liang, H; Sha, N, 2004)

Research

Studies (138)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.72)18.7374
1990's12 (8.70)18.2507
2000's36 (26.09)29.6817
2010's65 (47.10)24.3611
2020's24 (17.39)2.80

Authors

AuthorsStudies
Aksenov, AV1
Smirnov, AN1
Magedov, IV1
Reisenauer, MR1
Aksenov, NA1
Aksenova, IV1
Pendleton, AL1
Nguyen, G1
Johnston, RK1
Rubin, M1
De Carvalho, A1
Kiss, R2
Mathieu, V1
Lefranc, F2
Correa, J1
Cavazos, DA1
Brenner, AJ1
Bryan, BA1
Rogelj, S1
Kornienko, A1
Frolova, LV1
Xu, Z2
Zhao, SJ1
Liu, Y8
Torres, JP1
Lin, Z1
Fenton, DS1
Leavitt, LU1
Niu, C1
Lam, PY1
Robes, JM1
Peterson, RT1
Concepcion, GP1
Haygood, MG1
Olivera, BM1
Schmidt, EW1
Cao, C1
Yang, J1
Chen, Y7
Zhou, P1
Wang, Y5
Du, W1
Zhao, L1
Wang, H3
Ren, B1
Jiang, B1
Guo, Y1
Wei, M1
Luo, L2
Kuang, X1
Qiu, M1
Lv, L1
Xu, H1
Qi, R1
Yan, H1
Xu, D1
Wang, Z2
Huo, CX1
Zhu, Y2
Zhao, Y4
Wu, Y2
Qin, Z1
Su, D1
Tang, T1
Wang, F3
Sun, X3
Feng, Y1
Peng, H1
Wang, X7
Gao, Y3
Gong, W1
Yu, F1
Liu, X3
Wang, L2
Zhou, C1
Li, J8
Sun, Y2
Zhao, X1
Ma, Y3
Zhang, X5
Ramchandani, S1
Mohan, CD1
Mistry, JR1
Su, Q2
Naz, I1
Rangappa, KS1
Ahn, KS1
Altinoz, MA1
Ozpinar, A1
Wainberg, ZA1
Singh, AS1
Konecny, GE1
McCann, KE1
Hecht, JR1
Goldman, J1
Chmielowski, B1
Finn, RS1
O'Brien, N1
Von Euw, E1
Price, MM1
Martinez, D1
Yonemoto, L1
Brennan, M1
Glaspy, JA1
Slamon, DJ1
Metts, JL1
Trucco, M1
Weiser, DA1
Thompson, P1
Sandler, E1
Smith, T1
Crimella, J1
Sansil, S1
Thapa, R1
Fridley, BL1
Llosa, N1
Badgett, T1
Gorlick, R2
Reed, D1
Gill, J1
Cao, Y1
Jin, L2
Zhang, S3
Lv, Z1
Yin, N1
Zhang, H2
Zhang, T3
Zhao, G1
Douangprachanh, S1
Joo, HJ1
Park, HM1
Han, N1
Jang, HY1
Koh, YH1
Kim, TH1
Han, SS1
Park, SJ1
Lee, WJ1
Woo, SM1
Chun, JW1
Yu, SH3
Kan, ANC3
To, KF3
Lam, YL3
Yan, CLS3
Liu, APY3
Ku, DTL3
Dexheimer, TS1
Coussens, NP1
Silvers, T1
Wright, J1
Morris, J1
Doroshow, JH2
Teicher, BA1
Tanriverdi, O1
Ngo, MT1
Karvelis, E1
Harley, BAC1
Federico, SM1
Pappo, AS1
Sahr, N1
Sykes, A1
Campagne, O1
Stewart, CF2
Clay, MR1
Bahrami, A1
McCarville, MB2
Kaste, SC1
Santana, VM2
Helmig, S1
Gartrell, J1
Shelat, A1
Brennan, RC1
Hawkins, D1
Godwin, K1
Bishop, MW1
Furman, WL1
Stewart, E1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C3
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L4
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Ren, Y1
Li, P1
Jiao, Q1
Meng, P1
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Zhu, J3
Zhang, L3
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J4
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J3
Li, M1
Li, W2
Wu, W2
Du, F1
Ji, H1
Yang, X2
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Huang, H1
Wei, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS2
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J2
Kong, X1
Li, S3
Zhang, M4
Yang, T2
Dong, Y1
Xu, Y2
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y2
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J3
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J2
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J2
Shao, Z1
Yuan, C1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S2
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q2
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Forrest, WF1
Alicke, B1
Mayba, O1
Osinska, M1
Jakubczak, M1
Piatkowski, P1
Choniawko, L1
Starr, A1
Gould, SE1
Guyon, N1
Garnier, D1
Briand, J1
Nadaradjane, A1
Bougras-Cartron, G1
Raimbourg, J1
Campone, M2
Heymann, D1
Vallette, FM1
Frenel, JS1
Cartron, PF1
Lenz, LS1
Faccioni, JL1
Bracco, PA1
Santos, JAF1
Pereira, LC1
Buss, JH1
Tamborindeguy, MT1
Torgo, D1
Monteiro, T1
Mantovani, GB1
Santo, CN1
Marcolin, JC1
Dalsin, E1
Vigo, A1
Callegari-Jacques, SM1
Silva, AO1
Onzi, GR1
Begnini, KR1
Lenz, G1
Bacolod, MD1
Barany, F1
Chen, AP1
Kummar, S1
Moore, N1
Rubinstein, LV1
Williams, PM1
Palmisano, A1
Sims, D1
O'Sullivan Coyne, G1
Rosenberger, CL1
Simpson, M1
Raghav, KPS1
Meric-Bernstam, F1
Leong, S1
Waqar, S1
Foster, JC1
Konaté, MM1
Das, B1
Karlovich, C1
Lih, CJ1
Polley, E1
Simon, R1
Li, MC1
Piekarz, R1
Shi, C1
Diao, C1
Zhu, H1
Yuan, Q1
Liu, J1
Gu, M1
Chan, DL1
Bergsland, EK1
Chan, JA1
Gadgil, R1
Halfdanarson, TR1
Hornbacker, K1
Kelly, V1
Kunz, PL1
McGarrah, PW1
Raj, NP1
Reidy, DL1
Thawer, A1
Whitman, J1
Wu, L1
Becker, C1
Singh, S1
Tsakatikas, S1
Papageorgiou, G1
Fioretzaki, R1
Kosmas, C1
Nuthalapati, S1
Munasinghe, W1
Giranda, V1
Xiong, H1
Allison, SJ1
Sadiq, M1
Baronou, E1
Cooper, PA1
Dunnill, C1
Georgopoulos, NT1
Latif, A1
Shepherd, S1
Shnyder, SD1
Stratford, IJ1
Wheelhouse, RT1
Willans, CE1
Phillips, RM1
Senhaji Mouhri, Z1
Goodfellow, E1
Jean-Claude, B1
Miles, MA1
Hawkins, CJ1
Garza-Morales, R1
Yaddanapudi, K1
Perez-Hernandez, R1
Riedinger, E1
McMasters, KM1
Shirwan, H1
Yolcu, E1
Montes de Oca-Luna, R1
Gomez-Gutierrez, JG1
Houy, N2
Le Grand, F2
Pang, Y1
Pacak, K1
Yang, C1
Wilson, DL1
Beharry, AA1
Srivastava, A1
O'Connor, TR1
Kool, ET1
Xu, R1
Ji, Z1
Hoffman, RM2
Murakami, T1
Kawaguchi, K1
Igarashi, K1
Tan, Y1
Han, Q1
Kokkinakis, DM1
Frenkel, EP1
Babin, M1
Folliard, C1
Robert, J1
Sorrieul, J1
Kieffer, H1
Augereau, P1
Devys, C1
Nelson, B1
Liikanen, I1
Ahtiainen, L1
Hirvinen, ML1
Bramante, S1
Cerullo, V1
Nokisalmi, P1
Hemminki, O1
Diaconu, I1
Pesonen, S1
Koski, A1
Kangasniemi, L1
Pesonen, SK1
Oksanen, M1
Laasonen, L1
Partanen, K1
Joensuu, T1
Zhao, F1
Kanerva, A1
Hemminki, A1
Ekblad, T1
Camaioni, E1
Schüler, H1
Macchiarulo, A1
Venkatramani, R1
Malogolowkin, M1
Davidson, TB1
May, W1
Sposto, R1
Mascarenhas, L1
Scaringi, C1
De Sanctis, V1
Minniti, G1
Enrici, RM1
Gupte, M1
Tuck, AN1
Sharma, VP1
Williams, KJ2
Xiao, Y1
Ramiscal, J1
Kowanetz, K1
Del Nagro, C1
Malek, S1
Evangelista, M1
Blackwood, E1
Jackson, PK1
O'Brien, T1
Coker, SA1
Dandamudi, UB1
Beelen, AP1
Crosby, NA1
Fisher, JL1
Obrocea, M1
Ernstoff, MS1
Lewis, LD1
Polley, MY1
Freidlin, B1
Korn, EL1
Conley, BA1
Abrams, JS1
McShane, LM1
Bagatell, R1
Norris, R1
Ingle, AM2
Ahern, C1
Voss, S1
Fox, E3
Little, AR1
Weigel, BJ1
Adamson, PC2
Blaney, S1
Kapoor, S1
Rallabandi, VP1
Sakode, C1
Padhi, R1
Roy, PK1
Nieder, C1
Marienhagen, K1
Dalhaug, A1
Aandahl, G1
Haukland, E1
Pawinski, A1
Plummer, R2
Stephens, P1
Aissat-Daudigny, L1
Cambois, A1
Moachon, G1
Brown, PD1
Jiang, G2
Jiang, AJ1
Xin, Y2
Li, LT2
Zheng, JN2
Rangwala, R1
Leone, R1
Chang, YC1
Fecher, LA1
Schuchter, LM1
Kramer, A1
Tan, KS1
Heitjan, DF1
Rodgers, G1
Gallagher, M1
Piao, S1
Troxel, AB1
Evans, TL1
DeMichele, AM1
Nathanson, KL1
O'Dwyer, PJ1
Kaiser, J1
Pontiggia, L1
Davis, LE1
Amaravadi, RK1
Roix, JJ1
Harrison, SD1
Rainbolt, EA1
Meshaw, KR1
McMurry, AS1
Cheung, P1
Saha, S1
Jotte, RM1
Von Hoff, DD4
Braiteh, F1
Becerra, CR1
Richards, DA1
Smith, DA1
Garbo, L1
Stephenson, J1
Conkling, PR1
Robert-Vizcarrondo, F1
Turner, PK1
Chow, KH1
Tai, DF1
Ilaria, R1
Armstrong, JL1
Hill, DS1
McKee, CS1
Hernandez-Tiedra, S1
Lorente, M1
Lopez-Valero, I1
Eleni Anagnostou, M1
Babatunde, F1
Corazzari, M1
Redfern, CPF1
Velasco, G1
Lovat, PE1
Choudhury, KR1
Keir, ST2
Ashcraft, KA1
Boss, MK1
Dewhirst, MW1
Cioccoloni, G1
Bonmassar, L1
Pagani, E1
Caporali, S1
Fuggetta, MP1
Bonmassar, E1
D'Atri, S1
Aquino, A1
Tomaszowski, KH1
Schirrmacher, R1
Kaina, B1
McGonigle, S1
Chen, Z1
Chang, P1
Kolber-Simonds, D1
Ackermann, K1
Twine, NC1
Shie, JL1
Miu, JT1
Huang, KC1
Moniz, GA1
Nomoto, K1
Dullea, A1
Marignol, L1
Wickström, M1
Dyberg, C1
Milosevic, J1
Einvik, C1
Calero, R1
Sveinbjörnsson, B1
Sandén, E1
Darabi, A1
Siesjö, P1
Kool, M1
Kogner, P1
Baryawno, N1
Johnsen, JI1
Denies, S1
Cicchelero, L1
de Rooster, H1
Daminet, S1
Polis, I1
Van de Maele, I1
Sanders, NN1
He, JX1
Wang, M1
Huan, XJ1
Chen, CH1
Song, SS1
Wang, YQ1
Liao, XM1
Tan, C1
He, Q1
Tong, LJ1
Wang, YT1
Li, XH1
Su, Y1
Shen, YY1
Sun, YM1
Yang, XY1
Gao, ZW1
Chen, XY1
Xiong, B1
Lu, XL1
Ding, J1
Yang, CH1
Miao, ZH1
Thomas, A1
Tanaka, M1
Trepel, J1
Reinhold, WC1
Rajapakse, VN1
Pommier, Y1
Tamaskar, I1
Mekhail, T1
Dreicer, R1
Olencki, T1
Roman, S1
Elson, P1
Bukowski, RM1
Hollingshead, MG1
Jones, C1
Middleton, M1
Wilson, R1
Evans, J1
Olsen, A1
Curtin, N1
Boddy, A1
McHugh, P1
Newell, D1
Harris, A1
Johnson, P1
Steinfeldt, H1
Dewji, R1
Wang, D1
Robson, L1
Calvert, H1
Hennequin, C1
Quero, L1
Favaudon, V1
Meany, HJ1
Warren, KE2
Cole, DE1
Aikin, AA2
Balis, FM2
Trinh, VA1
Patel, SP1
Hwu, WJ1
Schiff, D1
Wen, PY1
van den Bent, MJ1
Ali, M1
Telfer, BA1
McCrudden, C1
O'Rourke, M1
Thomas, HD1
Kamjoo, M1
Kyle, S1
Robson, T1
Shaw, C1
Hirst, DG1
Curtin, NJ2
Zhuang, Z1
Lonser, R1
Kovach, JS1
Dasgupta, A1
McCarty, D1
Spencer, HT1
Wagner, LM2
Perentesis, JP1
Reid, JM4
Ames, MM4
Safgren, SL1
Nelson, MD1
Blaney, SM1
Rouleau, M1
Patel, A1
Hendzel, MJ1
Kaufmann, SH1
Poirier, GG1
Higgins, GS1
Prevo, R1
Lee, YF1
Helleday, T1
Muschel, RJ1
Taylor, S1
Yoshimura, M1
Hickson, ID1
Bernhard, EJ1
McKenna, WG1
McNall-Knapp, RY1
Williams, CN1
Reeves, EN1
Heideman, RL1
Meyer, WH1
Heshe, D1
Hoogestraat, S1
Brauckmann, C1
Karst, U1
Boos, J1
Lanvers-Kaminsky, C1
Rubie, H2
Geoerger, B2
Frappaz, D2
Schmitt, A1
Leblond, P1
Ndiaye, A1
Aerts, I1
Le Deley, MC1
Gentet, JC2
Paci, A1
Chastagner, P2
Dias, N1
Djafari, L2
Pasquet, M1
Chatelut, E1
Landman-Parker, J1
Corradini, N1
Vassal, G2
Bei, R1
Marzocchella, L1
Turriziani, M1
Banerjee, P1
Zhou, S1
Liu, D1
Yang, JG1
Zhao, LX1
Lee, SY1
Liu, S1
Mitchell, RM1
Slagle-Webb, B1
Hong, YS1
Sheehan, JM1
Connor, JR1
Gevertz, JL1
Portnow, J1
Frankel, P1
Koehler, S1
Twardowski, P1
Shibata, S1
Martel, C1
Morgan, R1
Cristea, M1
Chow, W1
Lim, D1
Chung, V1
Reckamp, K1
Leong, L1
Synold, TW1
Madhusudan, S1
Gagnon, J1
Dervisis, NG1
Kitchell, BE1
Zapletalova, D1
André, N1
Deak, L1
Kyr, M1
Bajciova, V2
Mudry, P2
Dubska, L1
Demlova, R1
Pavelka, Z2
Zitterbart, K2
Skotakova, J1
Husek, K1
Martincekova, A1
Mazanek, P2
Kepak, T2
Doubek, M1
Kutnikova, L1
Valik, D2
Sterba, J2
Savvides, P1
Gerson, SL3
Liu, YQ1
Tatar, Z1
Thivat, E1
Planchat, E1
Gimbergues, P1
Gadea, E1
Abrial, C1
Durando, X1
Roberge, D1
Souhami, L1
Fortin, MA1
Pouliot, JF1
Lopes, IC1
Oliveira, SC1
Oliveira-Brett, AM1
Hernández-Marqués, C1
Lassaletta-Atienza, A1
Ruiz Hernández, A1
Blumenfeld Olivares, JA1
Arce Abaitua, B1
Cormenzana Carpio, M1
Madero Lopez, L1
Maris, JM1
Reynolds, CP1
Kang, MH1
Kolb, EA1
Lock, R1
Carol, H1
Morton, CL1
Kurmasheva, RT1
Houghton, PJ2
Smith, MA1
Jones, SF2
Gian, VG2
Greco, FA2
Miranda, FT2
Shipley, DL1
Thompson, DS1
Hainsworth, JD2
Toomey, MA1
Willcutt, NT2
Burris, HA2
Rudek, MA1
Donehower, RC2
Statkevich, P7
Batra, VK2
Cutler, DL3
Baker, SD4
Crews, KR1
Iacono, LC1
Fuller, CE1
Goldsby, RE1
Albritton, K1
Hammond, LA3
Eckardt, JR3
Kuhn, JG1
Johnson, T2
Smith, L1
Drengler, RL1
Campbell, E1
Weiss, GR2
Rowinsky, EK4
Liang, H1
Sha, N1
Awada, A1
Gil, T1
Sales, F1
Dubuisson, M1
Vereecken, P1
Klastersky, J1
Moerman, C1
de Valeriola, D1
Piccart, MJ1
Payne, MJ1
Pratap, SE1
Middleton, MR3
Tentori, L1
Graziani, G1
De Sio, L1
Milano, GM1
Castellano, A1
Jenkner, A1
Fidani, P1
Dominici, C1
Donfrancesco, A1
Birner, A1
Raefsky, EL1
Beschorner, AF1
Kennerly, G1
Doz, F1
O'Quigley, J1
Wartelle, M1
Watson, AJ1
Raquin, MA1
Couanet, D1
Geoffray, A1
Margison, GP2
Pein, F1
Libucha, M1
Widemann, BC1
Packer, RJ1
Ranson, M1
Bridgewater, J1
Lee, SM1
Dawson, M1
Jowle, D1
Halbert, G1
Waller, S1
McGrath, H1
Gumbrell, L1
McElhinney, RS1
Donnelly, D1
McMurry, TB1
Marx, J1
Sabharwal, A1
Kim, JT1
Kim, JS1
Ko, KW1
Kong, DS1
Kang, CM1
Kim, MH1
Son, MJ1
Song, HS1
Shin, HJ1
Eoh, W1
Nam, DH1
Kadlecova, V1
Laber, DA1
Khan, MI1
Kloecker, GH1
Schonard, C1
Taft, BS1
Salvador, C1
Sinkovics, J1
Jun, HT1
Rex, K1
Radinsky, R1
Kendall, R1
Coxon, A1
Burgess, TL1
Facchini, V1
Wedge, SR2
Porteous, JK1
Newlands, ES3
Nicholson, HS1
Krailo, M1
Seibel, NL1
Liu-Mares, W1
Vezina, LG1
Ettinger, AG1
Reaman, GH1
Estlin, EJ1
Lashford, L1
Ablett, S1
Price, L1
Gowing, R1
Gholkar, A1
Kohler, J1
Lewis, IJ1
Morland, B1
Pinkerton, CR1
Stevens, MC1
Mott, M1
Stevens, R1
Newell, DR1
Walker, D1
Dicks-Mireaux, C1
McDowell, H1
Reidenberg, P5
Marco, A2
Batra, V3
Dugan, M4
Pearson, AD1
Brock, CS1
Bower, M1
Evans, H1
Colquhoun, I1
Roddie, M1
Glaser, M1
Brampton, MH2
Rustin, GJ2
Stevens, DC1
Rubin, J2
Dhodapkar, M1
Burch, PA1
Pitot, HC1
Buckner, JC1
Suman, VJ1
Wirth, M1
Alton, K1
Sartorius, SE1
Cutler, D2
Grochow, LB1
Britten, CD1
Agarwala, SS1
Barrington, R1
Diab, SG1
Villalona-Calero, M1
Fraass, U1
Eckhardt, SG2
Beale, P2
Judson, I2
Moore, S2
Brada, M2
Forral, K1
Rinaldi, DA1
Royce, ME1
Hoff, PM1
Pazdur, R1
Jen, JF1
Pai, SM1
Affrime, MB1
Zambas, DN1
Heft, S1
Hajian, G1
Spiro, TP1
Majka, S1
Haaga, J1
Willson, JK1
Skirvin, JA1
Lichtman, SM1
Blackledge, GR1
Slack, JA1
Smith, DB1
Stuart, NS1
Quarterman, CP1
Hoffman, R1
Stevens, MF1
Wilman, DE1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)[NCT00526617]Phase 141 participants (Actual)Interventional2007-08-31Completed
A Phase I Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin[NCT00993044]Phase 113 participants (Actual)Interventional2009-09-30Completed
PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037]Phase 239 participants (Actual)Interventional2020-04-07Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.)
A Phase 1 Multicenter, Dose-escalation Study of LY573636-sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors[NCT01284335]Phase 1234 participants (Actual)Interventional2008-07-31Terminated (stopped due to Study was terminated due to the termination of tasisulam development.)
Phase I Trial of Weekly Docetaxel and Daily Temozolomide in Patients With Metastatic Disease[NCT00401180]Phase 125 participants (Actual)Interventional2002-06-30Completed
Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors[NCT00020150]Phase 10 participants Interventional2000-06-30Completed
A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors[NCT00138216]Phase 142 participants (Actual)Interventional2005-10-31Completed
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors[NCT00544284]Phase 125 participants (Actual)Interventional2005-01-31Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]Phase 211 participants (Actual)Interventional2010-10-14Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
Phase II Randomized Study: Whole Brain Radiotherapy and Concomitant Temozolomide, Compared With Whole Brain Radiotherapy for Brain Metastases Treatment[NCT01015534]Phase 255 participants (Actual)Interventional2006-01-31Completed
Glioblastoma Lines as the Disease Model[NCT04180046]10 participants (Anticipated)Observational2019-06-26Recruiting
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]Phase 20 participants (Actual)Interventional2009-02-28Withdrawn (stopped due to No patients accrued since study opened)
Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075]Phase 225 participants (Actual)Interventional2002-07-31Completed
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Dose Limiting Toxicity

Number of participants with dose limiting toxicity events (NCT00993044)
Timeframe: 2 years

Interventionparticipants (Number)
Single Arm2

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)4
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Rate of Negative Tests at End of Treatment for COVID-19 Positive PCR Patients in Self-quarantine

Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)6
Sub Study 1 Group 2 (Placebo)0

Sub Study 1 - Secondary Infection of Co-inhabitants of COVID-19 Positive PCR Patients in Self-quarantine

Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers:Rate of Hospitalization

if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Sub Study 2:Number of Health Care Workers Testing Positive at 2 Months

Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.

InterventionParticipants (Count of Participants)
Sub Study 2 Group 1 (HCQ)0
Sub Study 2 Group 2 (Placebo)0

Substudy 1 - Number of COVID-19+ PCR Patients in Self-quarantine Who Are Hospitalized

Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.

InterventionParticipants (Count of Participants)
Sub Study 1 Group 1 (HCQ)0
Sub Study 1 Group 2 (Placebo)0

Sub Study 2:Health Care Workers: Assessment of Any Medical Events That Occur During the ~60 Day Active Period

Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.

,
InterventionParticipants (Count of Participants)
moderate adverse eventsminor adverse events
Sub Study 2 Group 1 (HCQ)21
Sub Study 2 Group 2 (Placebo)00

Number of Participants With Dose-Limiting Toxicities Cycle 1

A Dose-Limiting Toxicity (DLT) is defined as an Adverse Event (AE) that is likely related to the study medication or combination, and fulfills any one of the following criteria: Common Terminology Criteria for Adverse Events (CTCAE, Version 3.0) Grade 4 neutropenia lasting more than 5 days. Grade 4 neutropenia with fever or Grade 4 thrombocytopenia, regardless of duration; Grade ≥3 thrombocytopenia with bleeding, regardless of duration; Grade ≥3 nonhematologic toxicity (excluding nausea/vomiting or diarrhea that can be controlled with medication, and alopecia). Grade 3 electrolyte toxicity (for example, hypokalemia, hypophosphatemia) will not be considered a DLT unless it is considered related to the study drug or combination and does not resolve with standard replacement treatments within 42 days after Cycle 1 Day 1. A summary of other nonserious AEs and all Serious Adverse Events (SAE), regardless of causality is located in the Reported Adverse Event section. (NCT01284335)
Timeframe: Baseline to Cycle 1 (Up to Day 28)

InterventionParticipants (Count of Participants)
Arm A Tasisulam + Gemcitabine Dose Escalation4
Arm A Tasisulam + Gemcitabine Dose Confirmation0
Arm B* Tasisulam + Docetaxel Dose Escalation4
Arm B1 Tasisulam + Docetaxel Dose Escalation4
Arm B2 Tasisulam + Docetaxel Dose Escalation3
Arm B2 Tasisulam + Docetaxel Dose Confirmation0
Arm C Tasisulam + Temozolomide Dose Escalation3
Arm C Tasisulam + Temozolomide Dose Confirmation0
Arm D* Tasisulam + Cisplatin Dose Escalation0
Arm D Tasisulam + Cisplatin Dose Escalation2
Arm D Tasisulam + Cisplatin Dose Confirmation0
Arm E Tasisulam + Erlotinib Dose Escalation1
Arm E Tasisulam + Erlotinib Dose Confirmation0

Number of Participants With a Clinically Significant Effects

Clinically significant effects are reported if a Grade 3 or higher treatment emergent adverse event (TEAE) and observed in ≥10% of participants or a toxicity possibly related to study drug based on Common Terminology Criteria for Adverse Events (CTCAE). A summary of other nonserious AEs and all SAEs, regardless of causality is located in the Reported Adverse Event section. (NCT01284335)
Timeframe: Baseline to Study Completion (Up to 2 years)

,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
TEAE >/= Grade 3Toxicity >/= Grade 3
Arm A Tasisulam + Gemcitabine Dose Confirmation1818
Arm A Tasisulam + Gemcitabine Dose Escalation1513
Arm B* Tasisulam + Docetaxel Dose Escalation04
Arm B1 Tasisulam + Docetaxel Dose Escalation05
Arm B2 Tasisulam + Docetaxel Dose Confirmation1926
Arm B2 Tasisulam + Docetaxel Dose Escalation1618
Arm C Tasisulam + Temozolomide Dose Confirmation66
Arm C Tasisulam + Temozolomide Dose Escalation1113
Arm D Tasisulam + Cisplatin Dose Confirmation3030
Arm D Tasisulam + Cisplatin Dose Escalation87
Arm D* Tasisulam + Cisplatin Dose Escalation01
Arm E Tasisulam + Erlotinib Dose Confirmation77
Arm E Tasisulam + Erlotinib Dose Escalation55

Percentage of Participants With a Complete (CR) or Partial Response (PR) (Best Overall Tumor Response)

Best overall tumor response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. (NCT01284335)
Timeframe: Baseline to Study Completion (Up to 2 years)

Interventionpercentage of participants (Number)
Other
Arm C Tasisulam + Temozolomide Dose Confirmation0.0

Percentage of Participants With a Complete (CR) or Partial Response (PR) (Best Overall Tumor Response)

Best overall tumor response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. (NCT01284335)
Timeframe: Baseline to Study Completion (Up to 2 years)

Interventionpercentage of participants (Number)
Non-Small Cell Lung Cancer (NSCLC)Other
Arm B* Tasisulam + Docetaxel Dose Confirmation20.06.3

Percentage of Participants With a Complete (CR) or Partial Response (PR) (Best Overall Tumor Response)

Best overall tumor response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. (NCT01284335)
Timeframe: Baseline to Study Completion (Up to 2 years)

,
Interventionpercentage of participants (Number)
Non-Small Cell Lung Cancer (NSCLC)OtherPancreas
Arm A Tasisulam + Gemcitabine Dose Confirmation0.014.313.3
Arm E Tasisulam + Erlotinib Dose Confirmation0.014.30.0

Percentage of Participants With a Complete (CR) or Partial Response (PR) (Best Overall Tumor Response)

Best overall tumor response was evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions; Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions. (NCT01284335)
Timeframe: Baseline to Study Completion (Up to 2 years)

Interventionpercentage of participants (Number)
Non-Small Cell Lung Cancer (NSCLC)OtherPancreasSmall Cell Lung Cancer (SCLC)
Arm D Tasisulam + Cisplatin Dose Confirmation5.010.007.1

Pharmacokinetic (PK): Concentration Maximum (Cmax)

Cycle 2: predose,1h start of infusion, end of infusion, 30min,2h,4h,6h,22h,166h,334h,698h end of infusion. (NCT01284335)
Timeframe: Cycle 1: predose,0,30min,1h start of infusion, end of infusion, 30min,2h,4h,6h,22h,166h,334h,698h end of infusion.

Interventionmicrograms per milliliter (µg/mL) (Geometric Mean)
Cycle 1Cycle 2
Tasisulam306250

PK: Area Under the Curve Albumin (AUCalb)

Cycle 2: predose,1h start of infusion, end of infusion, 30min,2h,4h,6h,22h,166h,334h,698h end of infusion. (NCT01284335)
Timeframe: Cycle 1: predose,0,30min,1h start of infusion, end of infusion, 30min,2h,4h,6h,22h,166h,334h,698h end of infusion.

Interventionmicrograms*hour/milliliter (µg*h/mL) (Geometric Mean)
Cycle 1Cycle 2
Tasisulam946648

Safest Dose of Temozolomide for the DRBEAT Regimen

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

Interventiondose in mg/m^2 (Number)
DRBEAT Regimen773.25

One-year Progression-free Survival and Overall Survival

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

InterventionDays (Median)
Progression Free SurvivalOverall Survival
DRBEAT Regimen132564

Objective Response Rates. Assessed With Cranial MRI

"Objective Response (OR) encompassed the number of participants with Complete Response (CR) and the number of participants with Partial Response (PR). CR is the disappearance of all brain metastases, assessed between two or more cranial MRI. PR is at least a 30% decrease in the sum of the longest diameter of the brain metastases, taking as reference the baseline sum longest diameter, assessed between two or more cranial MRI.~Objective Response Rate (ORR) is the ratio between the number of participants with objective response and the total number of participants." (NCT01015534)
Timeframe: 90 days

InterventionPercentage of participants with OR (Number)
Whole Brain Irradiation and Temozolomide78.6
Whole Brain Irradiation48.1

Overall Survival

Overall survival:Time in months measured from treatment initiation until the date of death or the date of last follow-up. (NCT01015534)
Timeframe: 1 year

InterventionMonths of Overall Survival (Median)
Whole Brain Irradiation and Temozolomide8
Whole Brain Irradiation8.1

Survival Free of Brain Metastases Progression (PFS of BM)

Progression free survival of brain metastases is the survival of participants without progressive brain metastases or without neurological symptoms. The progressive brain metastases (PBM) were evaluated with cranial MRI. The PBM were defined as an increase of at least 20% in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new metastases. (NCT01015534)
Timeframe: at 90 days

InterventionPercentage of Participants (Number)
Whole Brain Irradiation and Temozolomide88.7
Whole Brain Irradiation83.7

Number of Grade 3-4 Adverse Events (AE) That Are Definitely or Probably Related to Both Groups of Treatment.

"AE, evaluated and graded according to the NCI common terminology criteria (NCI-CTCAE) v3.0~Grade 3 Severe AE.~Grade 4 Life-threatening or disabling AE." (NCT01015534)
Timeframe: 4 months

,
InterventionEvents (Number)
LeukopeniaLymphopeniaNausea-VomitingNeutropeniaPlatelets
Whole Brain Irradiation06010
Whole Brain Irradiation and Temozolomide111113

Overall Survival

(NCT00582075)
Timeframe: 2 years

Interventionweeks (Median)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide31

Percentage of Participants With Distant Brain Failure (DBF) at One Year

Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years

Interventionpercentage of participants (Number)
Radiosurgery 15-24 Gy + Adjuvant Temozolomide37

Reviews

26 reviews available for temozolomide and Neoplasms

ArticleYear
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tria

2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tria

2019
The multifaceted antineoplastic role of pyrimethamine against human malignancies.
    IUBMB life, 2022, Volume: 74, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Female; Humans; Neoplasms; Pyrimethamine; Temozolomide

2022
The multifaceted antineoplastic role of pyrimethamine against human malignancies.
    IUBMB life, 2022, Volume: 74, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Female; Humans; Neoplasms; Pyrimethamine; Temozolomide

2022
Oxamate targeting aggressive cancers with special emphasis to brain tumors.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glycolysis; Humans; L-Lactate Dehydrogenase; Mitochondri

2022
Oxamate targeting aggressive cancers with special emphasis to brain tumors.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glycolysis; Humans; L-Lactate Dehydrogenase; Mitochondri

2022
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
    Critical reviews in oncology/hematology, 2021, Volume: 166

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cam

2021
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
    Critical reviews in oncology/hematology, 2021, Volume: 166

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cam

2021
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
    Pharmacology & therapeutics, 2018, Volume: 188

    Topics: Animals; Combined Modality Therapy; DNA Repair; Drug Resistance, Neoplasm; Humans; Neoplasms; Poly(A

2018
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
    Pharmacology & therapeutics, 2018, Volume: 188

    Topics: Animals; Combined Modality Therapy; DNA Repair; Drug Resistance, Neoplasm; Humans; Neoplasms; Poly(A

2018
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
    Medicine, 2018, Volume: 97, Issue:46

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Da

2018
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
    Medicine, 2018, Volume: 97, Issue:46

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Da

2018
PARP inhibitors: polypharmacology versus selective inhibition.
    The FEBS journal, 2013, Volume: 280, Issue:15

    Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Catalytic Domain; Clinical Trials as Topic; Dacar

2013
PARP inhibitors: polypharmacology versus selective inhibition.
    The FEBS journal, 2013, Volume: 280, Issue:15

    Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Catalytic Domain; Clinical Trials as Topic; Dacar

2013
Temozolomide-related hematologic toxicity.
    Onkologie, 2013, Volume: 36, Issue:7-8

    Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse R

2013
Temozolomide-related hematologic toxicity.
    Onkologie, 2013, Volume: 36, Issue:7-8

    Topics: Antineoplastic Agents, Alkylating; Comorbidity; Dacarbazine; Drug-Related Side Effects and Adverse R

2013
Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
    Molecular biology reports, 2014, Volume: 41, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm;

2014
Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
    Molecular biology reports, 2014, Volume: 41, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm;

2014
MGMT testing allows for personalised therapy in the temozolomide era.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1

    Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Huma

2016
MGMT testing allows for personalised therapy in the temozolomide era.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:1

    Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Huma

2016
Temozolomide in the Era of Precision Medicine.
    Cancer research, 2017, 02-15, Volume: 77, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modificati

2017
Temozolomide in the Era of Precision Medicine.
    Cancer research, 2017, 02-15, Volume: 77, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Mismatch Repair; DNA Modificati

2017
[Biological basis of chemo-radiotherapy associations].
    Bulletin du cancer, 2009, Volume: 96, Issue:3

    Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DN

2009
[Biological basis of chemo-radiotherapy associations].
    Bulletin du cancer, 2009, Volume: 96, Issue:3

    Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DN

2009
The safety of temozolomide in the treatment of malignancies.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine;

2009
The safety of temozolomide in the treatment of malignancies.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine;

2009
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
Neurological adverse effects caused by cytotoxic and targeted therapies.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
PARP inhibition: PARP1 and beyond.
    Nature reviews. Cancer, 2010, Volume: 10, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; G

2010
PARP inhibition: PARP1 and beyond.
    Nature reviews. Cancer, 2010, Volume: 10, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; G

2010
The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action.
    Recent patents on anti-cancer drug discovery, 2010, Volume: 5, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Temozo

2010
The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action.
    Recent patents on anti-cancer drug discovery, 2010, Volume: 5, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Temozo

2010
Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
    Current medicinal chemistry, 2012, Volume: 19, Issue:23

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Hu

2012
Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
    Current medicinal chemistry, 2012, Volume: 19, Issue:23

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Hu

2012
Temozolomide and unusual indications: review of literature.
    Cancer treatment reviews, 2013, Volume: 39, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N

2013
Temozolomide and unusual indications: review of literature.
    Cancer treatment reviews, 2013, Volume: 39, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N

2013
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
    Critical reviews in oncology/hematology, 2005, Volume: 53, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; DNA Repair; Drug Administrat

2005
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
    Critical reviews in oncology/hematology, 2005, Volume: 53, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dacarbazine; DNA Repair; Drug Administrat

2005
PARP inhibitors for cancer therapy.
    Expert reviews in molecular medicine, 2005, Mar-15, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; DNA Repair; DNA, Neoplasm; Dr

2005
PARP inhibitors for cancer therapy.
    Expert reviews in molecular medicine, 2005, Mar-15, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dacarbazine; DNA Repair; DNA, Neoplasm; Dr

2005
Chemopotentiation by PARP inhibitors in cancer therapy.
    Pharmacological research, 2005, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Dacarbazine; DNA Damage; Drug Synergism; Enzyme Inhibitors; Humans;

2005
Chemopotentiation by PARP inhibitors in cancer therapy.
    Pharmacological research, 2005, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Agents; Dacarbazine; DNA Damage; Drug Synergism; Enzyme Inhibitors; Humans;

2005
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
    Current opinion in pharmacology, 2006, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DN

2006
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
    Current opinion in pharmacology, 2006, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DN

2006
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
    The oncologist, 2007, Volume: 12, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Ne

2007
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
    The oncologist, 2007, Volume: 12, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Ne

2007
Novel oral chemotherapy agents.
    Current oncology reports, 2000, Volume: 2, Issue:1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2000
Novel oral chemotherapy agents.
    Current oncology reports, 2000, Volume: 2, Issue:1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2000
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
    Drugs & aging, 2002, Volume: 19, Issue:1

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary

2002
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
    Drugs & aging, 2002, Volume: 19, Issue:1

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary

2002

Trials

44 trials available for temozolomide and Neoplasms

ArticleYear
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 01-04, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Irinotecan; Neoplasms; Temozolomide

2023
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 01-04, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Irinotecan; Neoplasms; Temozolomide

2023
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo

2023
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neo

2023
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 137

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female;

2020
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 137

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female;

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
    JCO precision oncology, 2021, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; D

2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
    JCO precision oncology, 2021, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; D

2021
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2018
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2018
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chi

2013
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chi

2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema

2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema

2013
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Presc

2014
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Presc

2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Autophagy, 2014, Volume: 10, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi

2014
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Autophagy, 2014, Volume: 10, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi

2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplati

2015
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
    Investigational new drugs, 2015, Volume: 33, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplati

2015
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
    Investigational new drugs, 2008, Volume: 26, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doce

2008
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
    Investigational new drugs, 2008, Volume: 26, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doce

2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; D

2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; D

2008
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Ch

2009
Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Ch

2009
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; C

2010
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; C

2010
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2010
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2010
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:15

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Hu

2010
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:15

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Hu

2010
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are

2012
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are

2012
Chemosensitized radiosurgery for recurrent brain metastases.
    Journal of neuro-oncology, 2012, Volume: 110, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male;

2012
Chemosensitized radiosurgery for recurrent brain metastases.
    Journal of neuro-oncology, 2012, Volume: 110, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Male;

2012
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Da

2003
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Da

2003
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
    Pharmacotherapy, 2004, Volume: 24, Issue:1

    Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Alkylating Agents; Area Under Curve; Biliru

2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
    Pharmacotherapy, 2004, Volume: 24, Issue:1

    Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Alkylating Agents; Area Under Curve; Biliru

2004
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-01, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Misma

2004
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-01, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Misma

2004
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Car

2004
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Car

2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
    Anti-cancer drugs, 2004, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ

2004
Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
    Anti-cancer drugs, 2004, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ

2004
Temozolomide in resistant or relapsed pediatric solid tumors.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-

2006
Temozolomide in resistant or relapsed pediatric solid tumors.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-

2006
A Phase I trial of protracted oral fixed-dose temozolomide.
    Cancer, 2005, Nov-01, Volume: 104, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine

2005
A Phase I trial of protracted oral fixed-dose temozolomide.
    Cancer, 2005, Nov-01, Volume: 104, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine

2005
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
    British journal of cancer, 2005, Sep-05, Volume: 93, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati

2005
Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
    British journal of cancer, 2005, Sep-05, Volume: 93, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati

2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-20, Volume: 23, Issue:30

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz

2005
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-20, Volume: 23, Issue:30

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbaz

2005
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5

    Topics: Adenosine Triphosphatases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

2006
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5

    Topics: Adenosine Triphosphatases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

2006
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
    Onkologie, 2006, Volume: 29, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera

2006
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.
    Onkologie, 2006, Volume: 29, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera

2006
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
    Cancer biology & therapy, 2007, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy

2007
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
    Cancer biology & therapy, 2007, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy

2007
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Dose-Res

1998
Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Dose-Res

1998
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
    British journal of cancer, 1998, Volume: 78, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cranial Irradiation; Dacarba

1998
Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.
    British journal of cancer, 1998, Volume: 78, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cranial Irradiation; Dacarba

1998
Phase I trial of temozolomide using an extended continuous oral schedule.
    Cancer research, 1998, Oct-01, Volume: 58, Issue:19

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration;

1998
Phase I trial of temozolomide using an extended continuous oral schedule.
    Cancer research, 1998, Oct-01, Volume: 58, Issue:19

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration;

1998
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:12 Pt 1

    Topics: Adult; Alkylating Agents; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; D

1997
Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:12 Pt 1

    Topics: Adult; Alkylating Agents; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; D

1997
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-

1997
Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-

1997
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:2

    Topics: Absorption; Administration, Oral; Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Al

1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:2

    Topics: Absorption; Administration, Oral; Adult; Aged; Aminoimidazole Carboxamide; Antineoplastic Agents, Al

1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administra

1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administra

1999
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Agents, Alkylating;

1999
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Agents, Alkylating;

1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine;

1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine;

1999
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    British journal of cancer, 1999, Volume: 81, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain

1999
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    British journal of cancer, 1999, Volume: 81, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain

1999
Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Do

2001
Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Area Under Curve; Dacarbazine; Do

2001
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
    British journal of cancer, 1992, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar

1992

Other Studies

69 other studies available for temozolomide and Neoplasms

ArticleYear
Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
    Journal of medicinal chemistry, 2015, Mar-12, Volume: 58, Issue:5

    Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Drug Resistance, Multiple; Drug Resist

2015
Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
    Journal of medicinal chemistry, 2015, Mar-12, Volume: 58, Issue:5

    Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Drug Resistance, Multiple; Drug Resist

2015
Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide.
    Journal of natural products, 2020, 04-24, Volume: 83, Issue:4

    Topics: Antineoplastic Agents; Biological Products; Calcium; Cytotoxins; Depsipeptides; Hypoxia; Molecular S

2020
Boholamide A, an APD-Class, Hypoxia-Selective Cyclodepsipeptide.
    Journal of natural products, 2020, 04-24, Volume: 83, Issue:4

    Topics: Antineoplastic Agents; Biological Products; Calcium; Cytotoxins; Depsipeptides; Hypoxia; Molecular S

2020
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
    Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Ligands; Mice; Neoplasms; Pht

2020
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
    Journal of medicinal chemistry, 2020, 10-08, Volume: 63, Issue:19

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Ligands; Mice; Neoplasms; Pht

2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24

    Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans;

2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24

    Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans;

2020
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
    Scientific reports, 2021, 08-30, Volume: 11, Issue:1

    Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre

2021
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
    Scientific reports, 2021, 08-30, Volume: 11, Issue:1

    Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre

2021
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Jan-01, Volume: 180

    Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti

2023
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Jan-01, Volume: 180

    Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti

2023
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo

2022
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo

2022
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:3

    Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide

2023
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.
    Cancer research communications, 2023, Volume: 3, Issue:8

    Topics: Ataxia Telangiectasia; DNA; DNA Repair; DNA-Activated Protein Kinase; Endothelial Cells; Humans; Neo

2023
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.
    Cancer research communications, 2023, Volume: 3, Issue:8

    Topics: Ataxia Telangiectasia; DNA; DNA Repair; DNA-Activated Protein Kinase; Endothelial Cells; Humans; Neo

2023
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
    Medical oncology (Northwood, London, England), 2020, Apr-24, Volume: 37, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immuno

2020
Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
    Medical oncology (Northwood, London, England), 2020, Apr-24, Volume: 37, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immuno

2020
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
    Integrative biology : quantitative biosciences from nano to macro, 2020, 06-19, Volume: 12, Issue:6

    Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer

2020
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
    Integrative biology : quantitative biosciences from nano to macro, 2020, 06-19, Volume: 12, Issue:6

    Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer

2020
Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology.
    Cancer research, 2020, 11-15, Volume: 80, Issue:22

    Topics: Anilides; Animals; Antineoplastic Agents, Alkylating; Bias; Decision Making; Disease Models, Animal;

2020
Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology.
    Cancer research, 2020, 11-15, Volume: 80, Issue:22

    Topics: Anilides; Animals; Antineoplastic Agents, Alkylating; Bias; Decision Making; Disease Models, Animal;

2020
Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells.
    Cell death & disease, 2020, 12-11, Volume: 11, Issue:12

    Topics: Aniline Compounds; Animals; Apoptosis; Bcl-2-Like Protein 11; Biomarkers, Tumor; Cell Death; Cell Li

2020
Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells.
    Cell death & disease, 2020, 12-11, Volume: 11, Issue:12

    Topics: Aniline Compounds; Animals; Apoptosis; Bcl-2-Like Protein 11; Biomarkers, Tumor; Cell Death; Cell Li

2020
Cancer Cell Fitness Is Dynamic.
    Cancer research, 2021, 02-15, Volume: 81, Issue:4

    Topics: Cell Cycle; Cell Proliferation; Cells, Cultured; Clone Cells; DNA Damage; Genetic Fitness; Humans; M

2021
Cancer Cell Fitness Is Dynamic.
    Cancer research, 2021, 02-15, Volume: 81, Issue:4

    Topics: Cell Cycle; Cell Proliferation; Cells, Cultured; Clone Cells; DNA Damage; Genetic Fitness; Humans; M

2021
MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
    Current cancer drug targets, 2021, Volume: 21, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Computational Biology; CpG Islands;

2021
MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types.
    Current cancer drug targets, 2021, Volume: 21, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Computational Biology; CpG Islands;

2021
Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

2021
Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Retrospective Studies; Temozolomi

2021
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Retrospective Studies; Temozolomi

2021
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.
    Cancer letters, 2017, 09-10, Volume: 403

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis

2017
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands.
    Cancer letters, 2017, 09-10, Volume: 403

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis

2017
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    BMC cancer, 2017, Aug-11, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tu

2017
A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    BMC cancer, 2017, Aug-11, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tu

2017
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
    Cell death & disease, 2017, 10-05, Volume: 8, Issue:10

    Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hyd

2017
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
    Cell death & disease, 2017, 10-05, Volume: 8, Issue:10

    Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hyd

2017
Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.
    Cancer biology & therapy, 2018, 03-04, Volume: 19, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Co

2018
Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.
    Cancer biology & therapy, 2018, 03-04, Volume: 19, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Co

2018
Administration of temozolomide: Comparison of conventional and metronomic chemotherapy regimens.
    Journal of theoretical biology, 2018, 06-07, Volume: 446

    Topics: Administration, Metronomic; Humans; Maximum Tolerated Dose; Models, Biological; Neoplasms; Temozolom

2018
Administration of temozolomide: Comparison of conventional and metronomic chemotherapy regimens.
    Journal of theoretical biology, 2018, 06-07, Volume: 446

    Topics: Administration, Metronomic; Humans; Maximum Tolerated Dose; Models, Biological; Neoplasms; Temozolom

2018
Optimal dynamic regimens with artificial intelligence: The case of temozolomide.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Algorithms; Antineoplastic Agents, Alkylating; Artificial Intelligence; Dose-Response Relationship,

2018
Optimal dynamic regimens with artificial intelligence: The case of temozolomide.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Algorithms; Antineoplastic Agents, Alkylating; Artificial Intelligence; Dose-Response Relationship,

2018
Fluorescence Probes for ALKBH2 Allow the Measurement of DNA Alkylation Repair and Drug Resistance Responses.
    Angewandte Chemie (International ed. in English), 2018, 09-24, Volume: 57, Issue:39

    Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alkylation; Antineoplastic Agents, Alkyla

2018
Fluorescence Probes for ALKBH2 Allow the Measurement of DNA Alkylation Repair and Drug Resistance Responses.
    Angewandte Chemie (International ed. in English), 2018, 09-24, Volume: 57, Issue:39

    Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alkylation; Antineoplastic Agents, Alkyla

2018
High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1866

    Topics: Animals; Body Weight; Carbon-Sulfur Lyases; Cell Proliferation; Humans; Mice, Nude; Mutation; Neopla

2019
High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1866

    Topics: Animals; Body Weight; Carbon-Sulfur Lyases; Cell Proliferation; Humans; Mice, Nude; Mutation; Neopla

2019
Total Methionine Restriction Treatment of Cancer.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1866

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Choline; Homocysteine; Humans; Liver; Methionine; Mic

2019
Total Methionine Restriction Treatment of Cancer.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1866

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Choline; Homocysteine; Humans; Liver; Methionine; Mic

2019
[Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks].
    Annales pharmaceutiques francaises, 2019, Volume: 77, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Delivery o

2019
[Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks].
    Annales pharmaceutiques francaises, 2019, Volume: 77, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Delivery o

2019
Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.
    Cancer cytopathology, 2013, Volume: 121, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Forecasting; Ganciclovir; Humans; Mice; Mol

2013
Targeting a murky cancer reservoir: more researchers set their sights on cancer stem cells.
    Cancer cytopathology, 2013, Volume: 121, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Forecasting; Ganciclovir; Humans; Mice; Mol

2013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2013, Volume: 21, Issue:6

    Topics: Adenosine Triphosphate; Adenoviridae; Adolescent; Adult; Aged; Animals; Antibodies, Neutralizing; An

2013
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2013, Volume: 21, Issue:6

    Topics: Adenosine Triphosphate; Adenoviridae; Adolescent; Adult; Aged; Animals; Antibodies, Neutralizing; An

2013
Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Cycle; Cell Line; Cell Line, Tumo

2013
Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Cycle; Cell Line; Cell Line, Tumo

2013
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbol

2013
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbol

2013
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dac

2013
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dac

2013
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
    Theoretical biology & medical modelling, 2013, Dec-26, Volume: 10

    Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re

2013
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
    Theoretical biology & medical modelling, 2013, Dec-26, Volume: 10

    Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re

2013
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged;

2014
Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Middle Aged;

2014
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; D

2014
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; D

2014
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
    The Journal of investigative dermatology, 2015, Volume: 135, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy;

2015
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
    The Journal of investigative dermatology, 2015, Volume: 135, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy;

2015
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
    Oncotarget, 2015, Jun-10, Volume: 6, Issue:16

    Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig

2015
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
    Oncotarget, 2015, Jun-10, Volume: 6, Issue:16

    Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig

2015
Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro.
    International journal of oncology, 2015, Volume: 47, Issue:2

    Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; H

2015
Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro.
    International journal of oncology, 2015, Volume: 47, Issue:2

    Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; H

2015
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
    Molecular pharmaceutics, 2015, Nov-02, Volume: 12, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western;

2015
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
    Molecular pharmaceutics, 2015, Nov-02, Volume: 12, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western;

2015
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Blotting, Western; Carboplat

2015
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Blotting, Western; Carboplat

2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Nature communications, 2015, Nov-25, Volume: 6

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele

2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
    Nature communications, 2015, Nov-25, Volume: 6

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele

2015
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
    Veterinary and comparative oncology, 2017, Volume: 15, Issue:2

    Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; Case-Control Studies; Cyclop

2017
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
    Veterinary and comparative oncology, 2017, Volume: 15, Issue:2

    Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; Case-Control Studies; Cyclop

2017
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
    Oncotarget, 2017, Jan-17, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell S

2017
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
    Oncotarget, 2017, Jan-17, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell S

2017
Antitumor efficacy testing in rodents.
    Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21

    Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistic

2008
Antitumor efficacy testing in rodents.
    Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21

    Topics: Animals; Antineoplastic Agents; Biological Availability; Dacarbazine; Data Interpretation, Statistic

2008
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Blood Vessels; C

2009
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Blood Vessels; C

2009
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
    Cell cycle (Georgetown, Tex.), 2009, Oct-15, Volume: 8, Issue:20

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Dacarbazine; DNA Breaks, Double-Stranded; DN

2009
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
    Cell cycle (Georgetown, Tex.), 2009, Oct-15, Volume: 8, Issue:20

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Cycle; Dacarbazine; DNA Breaks, Double-Stranded; DN

2009
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
    Biochemical and biophysical research communications, 2010, Jan-01, Volume: 391, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine

2010
Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.
    Biochemical and biophysical research communications, 2010, Jan-01, Volume: 391, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytotoxicity, Immunologic; Dacarbazine

2010
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
    Cancer research, 2010, Apr-01, Volume: 70, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Polymerase thet

2010
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.
    Cancer research, 2010, Apr-01, Volume: 70, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Polymerase thet

2010
Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; C

2011
Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; C

2011
Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment.
    Biomaterials, 2010, Volume: 31, Issue:29

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Diagnostic

2010
Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment.
    Biomaterials, 2010, Volume: 31, Issue:29

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Diagnostic

2010
Synthesis and antitumor activity of 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-carboxylates and -carboxamides.
    Molecules (Basel, Switzerland), 2010, Dec-20, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 2-Ring

2010
Synthesis and antitumor activity of 3-methyl-4-oxo-3,4-dihydroimidazo [5,1-d][1,2,3,5]tetrazine-8-carboxylates and -carboxamides.
    Molecules (Basel, Switzerland), 2010, Dec-20, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Dacarbazine; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 2-Ring

2010
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
    International journal of cancer, 2011, Nov-01, Volume: 129, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin

2011
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
    International journal of cancer, 2011, Nov-01, Volume: 129, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin

2011
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
    Computational and mathematical methods in medicine, 2011, Volume: 2011

    Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani

2011
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
    Computational and mathematical methods in medicine, 2011, Volume: 2011

    Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani

2011
Evolving drug targets in DNA base excision repair for cancer therapy.
    Current molecular pharmacology, 2012, Volume: 5, Issue:1

    Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; BRCA2 Protein; Dacarbazine; DNA Repair; Humans; Ne

2012
Evolving drug targets in DNA base excision repair for cancer therapy.
    Current molecular pharmacology, 2012, Volume: 5, Issue:1

    Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; BRCA2 Protein; Dacarbazine; DNA Repair; Humans; Ne

2012
Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
    Journal of feline medicine and surgery, 2012, Volume: 14, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Dacarbazine; Doxorubici

2012
Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
    Journal of feline medicine and surgery, 2012, Volume: 14, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Dacarbazine; Doxorubici

2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Oncology, 2012, Volume: 82, Issue:5

    Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chem

2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.
    Oncology, 2012, Volume: 82, Issue:5

    Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chem

2012
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Jul-15, Volume: 901

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Tria

2012
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Jul-15, Volume: 901

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Tria

2012
In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:11

    Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Biosensing Techniques; Dacarbazine; D

2013
In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:11

    Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Biosensing Techniques; Dacarbazine; D

2013
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
    Anales de pediatria (Barcelona, Spain : 2003), 2013, Volume: 79, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Com

2013
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
    Anales de pediatria (Barcelona, Spain : 2003), 2013, Volume: 79, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Com

2013
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylas

2013
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylas

2013
Modeling antitumor activity by using a non-linear mixed-effects model.
    Mathematical biosciences, 2004, Volume: 189, Issue:1

    Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2004
Modeling antitumor activity by using a non-linear mixed-effects model.
    Mathematical biosciences, 2004, Volume: 189, Issue:1

    Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2004
Author comments on drug-dispensing change.
    Clinical journal of oncology nursing, 2005, Volume: 9, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neoplasms; Patient Edu

2005
Author comments on drug-dispensing change.
    Clinical journal of oncology nursing, 2005, Volume: 9, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neoplasms; Patient Edu

2005
Autophagy: is it cancer's friend or foe?
    Science (New York, N.Y.), 2006, May-26, Volume: 312, Issue:5777

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Survival; C

2006
Autophagy: is it cancer's friend or foe?
    Science (New York, N.Y.), 2006, May-26, Volume: 312, Issue:5777

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Survival; C

2006
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
    Oncology reports, 2006, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models

2006
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
    Oncology reports, 2006, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models

2006
[The effect of oxygenation on the biological behaviour of tumours].
    Orvosi hetilap, 2007, Oct-28, Volume: 148, Issue:43

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2007
[The effect of oxygenation on the biological behaviour of tumours].
    Orvosi hetilap, 2007, Oct-28, Volume: 148, Issue:43

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2007
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-15, Volume: 13, Issue:22 Pt 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2007
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-15, Volume: 13, Issue:22 Pt 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2007
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    British journal of cancer, 1996, Volume: 74, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening A

1996
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    British journal of cancer, 1996, Volume: 74, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening A

1996
Population pharmacokinetics of temozolomide in cancer patients.
    Pharmaceutical research, 2000, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Body Fluid Compartments; Clinical Trials, Phase I as

2000
Population pharmacokinetics of temozolomide in cancer patients.
    Pharmaceutical research, 2000, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Body Fluid Compartments; Clinical Trials, Phase I as

2000
Prodrugs in cancer chemotherapy.
    Biochemical Society transactions, 1986, Volume: 14, Issue:2

    Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chem

1986
Prodrugs in cancer chemotherapy.
    Biochemical Society transactions, 1986, Volume: 14, Issue:2

    Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chem

1986